Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CFD | P00746 | 4/20 | 0.39 |
| ▸ | TPSB2 | P20231 | 4/20 | 0.39 |
| ▸ | F11 | P03951 | 3/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20540841 | 0.87 | COMT (0.41) | COMTGSTP1MAPK14 | |
| SCHEMBL20540620 | 0.86 | COMT (0.40) | COMTGSTP1MAPK14 | |
| SCHEMBL28905755 | 0.86 | COMT (0.40) | COMTSMN1; SMN2GSTP1MAPK14 | |
| SCHEMBL28503026 | 0.85 | COMT (0.40) | COMTGSTP1MAPK14 | |
| SCHEMBL28513996 | 0.84 | COMT (0.38) | COMTMAPK14 | |
| SCHEMBL28507869 | 0.83 | COMT (0.45) | COMTKMT2AGSTP1MAPK14 | |
| SCHEMBL28501964 | 0.82 | COMT (0.39) | COMTGSTP1MAPK14ABCB1ABCG2 | |
| SCHEMBL28905753 | 0.82 | TYR (0.41) | COMTMAPK14 | |
| SCHEMBL9652539 | 0.82 | MAPK14 (0.49) | COMTKMT2ASMN1; SMN2GSTP1MAPK14 | |
| SCHEMBL20540920 | 0.81 | COMT (0.49) | COMTGSTP1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3380471-B1 | TETRAHYDRO-8H-PYRIDO[1,2-A]PYRAZINE-8-ONES AS COMT INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | LIEBER INST INC DBA LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | LIEBER INST INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | LIEBER INST INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20180305354-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305354-A1 | COMT Inhibiting Methods and Compositions | COMT, MAOB, MAOA | COMT 1/4885KMT2A 618/4885SMN1; SMN2 426/4885 |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | COMT, PNMT, HNMT | COMT 1/4885KMT2A 58/4885SMN1; SMN2 366/4885 |
| US-10934283-B2 | COMT inhibiting methods and compositions | COMT, MAOB, MAOA | COMT 1/4885KMT2A 618/4885SMN1; SMN2 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.